Canada Pharmaceutical Market Insight, Growth Report, 2024-2032
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
Market Statistics
The canada pharmaceutical market size and share was valued at USD 48.62 billion in 2023. The market is anticipated to grow from USD 51.72 billion in 2024 to USD 88.11 billion by 2032, exhibiting a CAGR of 6.9% during the forecast period
Canada Pharmaceutical Market Overview
The Canadian pharmaceutical market is propelled by various factors, such as a rising aging population, an increase in healthcare spending, a growing need for innovative drugs, and a significant emphasis on research and development. Furthermore, supportive government policies facilitating healthcare access and substantial investments in biotechnology play a crucial role in fostering the expansion of the market. These combined elements contribute to the continual growth and progress observed within the Canadian pharmaceutical industry.
The burgeoning elderly population in Canada stands out as a pivotal force propelling the pharmaceutical market forward. With a projected surge in the number of Canadians reaching the age of 65, expected to reach 5.1 million over the next decade, there is a substantial anticipated increase in the demand for pharmaceutical products and healthcare services. The elderly demographic, characterized by a higher prevalence of chronic health conditions and age-related ailments, underscores the imperative for pharmaceutical companies to focus on developing tailored drugs and healthcare solutions. This demographic shift underscores the prominence of geriatric medicine and healthcare services, playing a pivotal role in shaping the landscape of the Canadian pharmaceutical market.
The research study provides a comprehensive analysis of the industry, assessing the market on the basis of various segments and sub-segments. It sheds light on the competitive landscape and introduces Canada pharmaceutical market key players from the perspective of market share, concentration ratio, etc. The study is a vital resource for understanding the growth drivers, opportunities, and challenges in the industry.
To Understand More About this Research: Download Sample Report
The rising need for early and accurate disease diagnosis, coupled with an increasing demand for advanced therapies, is anticipated to drive market growth. According to data from the Canadian Cancer Society, cancer stands as the leading cause of death in Canada, contributing to over 28% of annual fatalities. In 2022, Canada reported approximately 233,900 new cancer cases and 85,100 cancer-related deaths. Among these, around 121,100 men and 112,800 women received cancer diagnoses. The prevalent types of cancer in the country include lung, breast, colorectal, and prostate cancers.
Cancer and cardiovascular diseases stand as the primary culprits behind fatalities in Canada. A notable 18.5% of the total annual deaths in the nation can be attributed to cardiovascular diseases. The escalating incidence and mortality rates of cancer and heart-related ailments are contributing to the expansion of the nuclear medicine and radiopharmaceutical market. As per data released by the Canadian Institute for Health Information (CIHI) in July 2022, approximately 2.4 million individuals in the country are grappling with heart disease. Additionally, the Heart and Stroke Foundation of Canada reveals that 9 out of 19 Canadians possess at least one risk factor predisposing them to heart conditions, stroke, and vascular cognitive impairment.
The economic burden of cardiovascular disease in Canada totals approximately USD 21.2 billion, encompassing both direct and indirect costs, while stroke incurs an annual cost of around USD 3.6 billion. Furthermore, the Canadian Institute for Health Information (CIHI) has partnered with the Canadian Cardiovascular Society (CCS) with the aim of enhancing the quality of cardiac care services nationwide. With government entities launching supportive initiatives and a rising prevalence of targeted diseases accompanied by elevated mortality rates, the demand for innovative and efficacious therapeutic products is anticipated to surge in the forthcoming years.
Market Dynamics
A Rise in the Elderly Population Bolstered the Growth of the Canada Pharmaceutical Market
The growing number of elderly individuals, who are more susceptible to various metabolic and lifestyle disorders, is contributing to an increase in the occurrences of chronic diseases within the Canadian population. The associated comorbidities with these diseases are expected to have a favorable impact on the pharmaceutical market's growth in the forecast period. The pharmaceutical industry in Canada is continually advancing, incorporating technologies like automated dispensing systems and electronic prescription systems. These innovations have the potential to enhance efficiency and accuracy, thereby fueling market expansion.
Market Restraints
Intensely Competitive, and Numerous Pharmacies are Competing for Customers are Likely to Hamper the Growth of the Market
Pharmacies face challenges in distinguishing themselves from competitors and drawing in customers due to the heightened competition. The recent surge in the number of pharmacies in Canada has resulted in market saturation in certain regions, posing difficulties in both attracting and retaining customers. Government regulations play a significant role in the heavily regulated pharmaceutical industry in Canada, acting as barriers for new pharmacies to enter the market and limiting the operational scope of existing ones.
Report Segmentation
The market is primarily segmented based on drug type, route of administration, disease, formulation, end-use.
| By Drug Type | By Route of Administration | By Disease | By Formulation | By End-Use |
|
|
|
|
|
To Understand the Scope of this Report: Request Customization
Canada Pharmaceutical Market Segmental Analysis
By Drug Type Analysis
- In 2023, the largest market share was held by the segment of conventional drugs (small molecules) based on drug type. Small molecules play a crucial role in driving Canada's pharmaceutical market, serving as the cornerstone of drug development and contributing to ongoing research and innovation in the sector. Their effectiveness in treating various medical conditions contributes to sustained high demand, fostering market growth and ensuring economic stability. Additionally, substantial investments and strategic partnerships enhance Canada's standing in the pharmaceutical industry, facilitating the creation of innovative medications and advancing the nation's impact on healthcare solutions worldwide.
- Furthermore, the growth of the segment will be accelerated by strategic initiatives undertaken by key market players. For instance, in April 2023, the global pharmaceutical company Takeda engaged in an exclusive licensing agreement with Treventis for a set of small molecules designed to target tau, a protein associated with misfolding and aggregation believed to contribute to Alzheimer's disease. Leveraging Treventis' expertise in Alzheimer's and neurodegenerative research, these molecules were developed. The significance of this collaboration lies in the potential to create an effective drug targeting tau in the brain, an area currently lacking suitable treatments. With prevalent brain-related conditions in Canada, such as Alzheimer's, Parkinson's, and epilepsy, this partnership holds promise for advancing treatments and finding cures through state-of-the-art patient care and research endeavors.
By Route of Administration Analysis
- In the forecast period, the oral route of administration emerged as the leading revenue contributor in the market. This method of delivering medications is widely preferred due to its non-invasive nature, cost-effectiveness, and ability to promote patient compliance. The versatility of oral medications across various medical conditions solidifies the prominence of this administration route, ensuring broad accessibility and effectiveness in drug delivery. The impact of these factors is pivotal in shaping pharmaceutical markets, enhancing treatment accessibility, and providing a user-friendly experience for patients.
- The parenteral segment is projected to experience the most rapid CAGR throughout the forecast period. This administration method entails directly injecting medications into the bloodstream, bypassing the digestive system. It plays a crucial role in ensuring swift drug delivery, and precise dosing, and is particularly valuable in situations demanding immediate and consistent blood levels. Parenteral routes, encompassing intravenous and intramuscular injections, are indispensable in critical care, emergency scenarios, and for patients facing challenges in swallowing or absorbing oral medications, thus serving as an essential component in modern medicine.
Competitive Landscape
The Canada Pharmaceutical market trend is fragmented and is anticipated to witness competition due to several players' presence. Major service providers in the market are constantly upgrading their technologies to stay ahead of the competition and to ensure efficiency, integrity, and safety. These players focus on partnership, product upgrades, and collaboration to gain a competitive edge over their peers and capture a significant market share.
Some of the major players operating in the global market include:
- AbbVie, Inc.
- AstraZeneca
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sanofi
Recent Developments
- In January 2025, Sandoz Canada, a Novartis subsidiary, introduced its biosimilar adalimumab, Hulio, to the Canadian market, representing the first biosimilar introduction in the country for treating inflammatory conditions patients nationwide (Sandoz, 2025).
- In October 2024, Shoppers Drug Mart, a prominent Canadian pharmacy retailer, formed a strategic collaboration with Curative Health Services to broaden its Healthcare Services and provide COVID-19 testing nationwide throughout its stores (Shoppers Drug Mart, 2024).
- In October 2022, Alvotech and the JAMP Pharma Group, a Canadian pharmaceutical company, expanded their exclusive partnership for the commercialization of biosimilars (AVT16 & AVT33) developed and manufactured by Alvotech.
- In June 2023, Becton, Dickinson, and Company concluded the transaction by selling its surgical instrumentation, laparoscopic instrumentation, and sterilization container assets to STERIS plc.
- In February 2022, CooperSurgical completed the acquisition of Cook Medical's reproductive health portfolio for a significant sum of USD 875 million. This portfolio includes a variety of medical equipment tailored for fertility, obstetrics, gynecology, and in vitro fertilization (IVF).
Report Coverage
The Canada Pharmaceutical market report emphasizes key regions across the globe to provide a better understanding of the product to the users. Also, the report provides market insights into recent developments and trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers an in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides a detailed analysis of the market while focusing on various key aspects such as competitive analysis, drug type, route of administration, disease, formulation, end-use, and futuristic growth opportunities.
Canada Pharmaceutical Market Report Scope
| Report Attributes | Details |
| Market size value in 2024 | USD 51.72 billion |
| Revenue Forecast in 2032 | USD 88.11 billion |
| CAGR | 6.9% from 2024 – 2032 |
| Base year | 2023 |
| Historical data | 2019 – 2022 |
| Forecast period | 2024 – 2032 |
| Quantitative units | Revenue in USD billion and CAGR from 2024 to 2032 |
| Segments Covered | By Drug Type, By Route of Administration, By Disease, By Formulation, By End-Use, By Region |
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Uncover the dynamics of the Canada pharmaceutical sector in 2024 with detailed statistics on market share, size, and revenue growth rate meticulously curated by Polaris Market Research Industry Reports. This all-encompassing analysis extends to a forward-looking market forecast until 2032, complemented by a perceptive historical overview. Immerse yourself in the profound insights offered by this industry analysis through a Download Sample Report.
Browse Our Top Selling Reports
Ovulation Testing Kits Market Size, Share 2024 Research Report
Halloysite Market Size, Share 2024 Research Report
Chemoinformatics Market Size, Share 2024 Research Report
FAQ's
key companies in Canada Pharmaceutical Market AbbVie, AstraZeneca, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline
Canada Pharmaceutical Market exhibiting the CAGR of 6.9% during the forecast period
The Canada Pharmaceutical Market report covering key segments are drug type, route of administration, disease, formulation, end-use
key driving factors in Canada Pharmaceutical Market are A rise in the elderly population
The global Canada Pharmaceutical market size is expected to reach USD 88.11 billion by 2032
Research Methodology
A robust system of research, verification, and forecasting designed to ensure reliable and actionable market insights.
Polaris Market Research & Consulting, Inc. uses a clear and structured approach to deliver insights that clients can rely on. The process combines detailed primary and secondary research, including direct communication with industry experts. The detailed information helps build a complete picture of market trends and developments. Secondary data is gathered from credible sources such as industry reports, company filings, government source links, and trusted organization databases. It is then cross-checked through discussions with key stakeholders across the value chain. Market size and forecasts are developed using both bottom-up and top-down methods to ensure accuracy and consistency in the final results.
1. Project Setup
Step 1 & 2:
- We start every project by clearly understanding the client’s objective or goal, then defining the market scope, and aligning regions, segments, and timelines.
- Once the foundation is set, we collect data from all-around of sources, including company reports, government databases, and paid industry platforms.
- Our research is based on secondary data, which helps us build a strong understanding of the market across regions and industries. Then we validate this information through primary research by speaking directly with industry experts, companies, and stakeholders.
- By combining secondary and primary research, we ensure that our market insights are accurate, practical, and closely aligned with real market conditions.
2. Data Collection
We gather information from both public and verified sources:
3. Data Structuring
Step 3:
- All collected data is organized into a consistent format to ensure accurate analysis. Since inputs come from multiple sources, they are standardized and aligned before use.
- The data is segmented by product, application, and region, and mapped across a defined historical period (2020–2024). All values are converted into common units (USD Mn/Bn), and volume and pricing are aligned where required to estimate revenue.
- Any overlaps or inconsistencies are reviewed and adjusted to maintain accuracy (<5% variance threshold).
- The result is a structured dataset that allows for clear comparison across regions and supports reliable analysis and forecasting.
Structured Market Dataset, USD Mn/Bn
| Region | Segment | VolumeUnits | Avg PriceUSD | RevenueUSD Mn | Share % |
|---|---|---|---|---|---|
| North America | Product A | 250 | 2.5 | 500 | 15% |
| Product A | XX | XX | XX | XX | |
| Product A | XX | XX | XX | XX | |
| Consistent methodology applied across regions | |||||
4. Market Estimation
Step 4: TOP-DOWN APPROACH
- We start with the overall market size at a global or macro level.
- The market is then narrowed down based on scope and industry relevance.
- We apply penetration rates and split the data by region and segment.
- This helps us estimate the market size for specific segments.
- The numbers are validated through cross-checks to ensure accuracy.
Step 5: BOTTOM-UP APPROACH
- We begin by analyzing data from leading companies in the market.
- Revenue data is collected and mapped across different segments.
- The data is then aggregated to estimate the total market size.
- To fill in any gaps, adjustments are made based on industry standards.
- Validation checks make sure that the results are correct.
5. Forecasting
Step 6:
At Polaris Market Research & Consulting, Inc., we employ a methodical forecasting strategy. This approach blends the analysis of historical data with real-time market validation. To forecast future trends with precision, we examine past patterns, pricing fluctuations, and the interplay of supply and demand. To ensure our conclusions reflect the present market landscape, we actively seek input from industry experts and key stakeholders.
To refine our predictions, we carefully consider critical elements such as market drivers and restraints, fluctuations in raw material costs, emerging technologies, and the production capabilities of various regions. Furthermore, we assess regulatory frameworks and potential policy shifts to gauge their potential impact on market expansion.
All this information is synthesized to generate precise forecasts for each segment and region. These forecasts illuminate the current state of the market and highlight forthcoming opportunities.
6. Validation & Triangulation
Step 7:
In the final stage, we validate all our estimates using a triangulation method, where data is cross-checked from multiple reliable sources, like company data, primary interviews, and secondary research. This helps us make sure that our numbers are correct and fit with the rest of the market.
This process involves verifying data consistency across various segments and geographic areas. It also requires comparing historical trends with the assumptions support the forecast. Any discrepancies involve adjustments to ensure everything remains aligned and dependable.
Once the data is finalized, we prepare the final outputs, including market size estimates, segment-wise breakdowns, and growth metrics. These are delivered in structured formats such as tables, charts, and data files for easy analysis and use.
We collaborate closely with clients, ensuring the final products align with their requirements. This includes offering tailored adjustments, supplementary data analyses, and continuous assistance. Furthermore, we monitor market trends post-delivery, providing updates and refinements to maintain the insights' relevance as time passes.
Triangulation Framework
Estimates are cross-verified across three sources:
Company-level data
• Primary inputs from industry participants
• Secondary benchmarks and published data
Variance maintained within +5-10%
Adjustments applied to align estimates
Segment values validated against overall market structure
Data Consistency & Integrity
Segment totals validated to 100%
Regional estimates aligned with global market size
Historical trends compared against forecast outputs
Assumptions reviewed for cross-segment and regional alignment
Final Outputs
Deliverables
Client Alignment & Support
- Deliverables are aligned with defined client requirements and scope
- Custom data cuts and segment splits are incorporated as required
- Post-delivery queries are addressed through analyst interactions
- Additional clarifications and data support are provided upon request
Client Continuity & Updates
- Market developments are tracked post-delivery to capture changes in key trends
- Updated data and revisions are provided based on new market inputs
- Additional refinements and data cuts are shared as required
- Continued analyst engagement supports evolving client requirements
Download Sample Report of Canada Pharmaceutical Market
Please fill out the form to request a customized copy of the research report.
